Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

Diabetes Care

Volumn 24, Issue 8, 2001, Pages 1416-1421

  Larsen, Jens ^a   Hylleberg, Birgitte ^a   Ng, Kevin ^b   Damsbo, Peter ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE FRAGMENT; PLACEBO; PROTEIN PRECURSOR; SULFONYLUREA DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INPATIENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; PROTEIN PRECURSORS; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 0035432607     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.8.1416     Document Type: Article

References (13)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet ii.1300, 1987
2. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfelt W: Additive insulinotropic effect of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like pepdide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
3. Larsen J, Nader J, Damsbo P: One-week continuous infusion of GLP-1(7-37) improves the glycaemic control in NIDDM (Abstract). Diabetes 45 (Suppl. 2):233A, 1996
4. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W: Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulphonylurea secondary failure. Diabetes Care 21:1925-1931, 1998
5. Nauck MA, Wollschläger, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Wilms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
6. Toft-Nielsen M-B, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143, 1999
7. Todd JF, Wilding JPH, Edwards CBM, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
8. Rachman J, Barrow BA, Levy JC, Turner JC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211, 1997
9. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
10. Nauck MA, Weber I, Bach I, Richter S, Ørskov C, Holst JJ, Schmiegel W: Normalization of fasting glycaemia with intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 15: 937-945, 1998
11. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of Glucagonlike Peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care: 15:270-276, 1992
12. Nauck MA, Kleine N, Ørskov C, Holst JJ, Wilms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (6-36 amide) in type 2 diabetic patients. Diabetologia 36: 741-744, 1993
13. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998